Melanóma: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• PD-1 54
• BRAF 18
• PD-L1 21
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• RAS 2
• CTNNB1 0
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

3285 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spanyolország· EU contribution 150 000 EUR· until 2028. ápr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Light-triggered Ultra-precise Carbon-enhanced phycocyanin Engineered Needles for Therapy (LUCENT)

  Univerzita Palackeho V Olomouci· Olomouc, Csehország· EU contribution 191 918 EUR· until 2028. aug.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeted therapy to block melanoma progression through peptide phage-display profiling of melanoma cells and derived extracellular vesicles (Target-MelaneX)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugália· EU contribution 207 183 EUR· until 2028. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  THz-FIR Colour Imaging of Skin Condition Based on Analysis of Its Thermal Emission (THz-Skin)

  Ita-Suomen Yliopisto· Kuopio, Finnország· EU contribution 2 998 913 EUR· until 2030. jan.· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Capturing UV Sunlight Using Hydrogen-Bond Networks: Organic Sun Screens for Skin Protection (CUSHOSP)

  United Nations Educational Scientific and Cultural Organization· Paris, Franciaország· EU contribution 150 000 EUR· until 2027. jún.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 12 running projects, newest first. Listed amounts together: 11,7 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

  NCT05075993· M.D. Anderson Cancer Center· Frissítve: 2026. nov. 10.

  “\<75% participation”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  NCT04318717· Washington University School of Medicine· Frissítve: 2026. nov. 6.

  “protocol amendment”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

  NCT07803562· University of California, San Diego· Frissítve: 2026. nov. 6.

  “Lack of funding”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

  NCT06673095· OHSU Knight Cancer Institute· Frissítve: 2026. okt. 20.

  “Pending coordinating center transition”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  NCT05879822· Incyte Corporation· Frissítve: 2026. okt. 20.

  “This was a strategic business decision. There were no safety concerns contributing to this decision.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases

  NCT05669352· Mayo Clinic· Frissítve: 2026. okt. 20.

  “transition to new institution”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

  NCT06365619· University of Utah· Frissítve: 2026. okt. 19.

  “Low Accrual”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

  NCT04866810· National Cancer Institute (NCI)· Frissítve: 2026. okt. 19.

  “On hold pending planned interim analysis.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Agenus Inc.· Frissítve: 2026. okt. 19.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

  NCT06566092· Iovance Biotherapeutics, Inc.· Frissítve: 2026. okt. 16.

  “After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

  NCT00923026· National Cancer Institute (NCI)· Forrás

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Forrás

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

  NCT05155033· National Cancer Institute (NCI)· Forrás

• Harvesting Cells for Experimental Cancer Treatments

  NCT00068003· National Cancer Institute (NCI)· Forrás

• Evaluation for NCI Surgery Branch Clinical Research Protocols

  NCT00001823· National Cancer Institute (NCI)· Forrás

• Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

  NCT05111574· National Cancer Institute (NCI)· Forrás

• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

  NCT05136196· National Cancer Institute (NCI)· Forrás

• A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

  NCT04708418· National Cancer Institute (NCI)· Forrás

• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

  NCT06961006· Merck Sharp & Dohme LLC· Forrás

• Dabrafenib and/or Trametinib Rollover Study

  NCT03340506· Novartis Pharmaceuticals· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 22
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 47
• Metabolomics 20
• Mass Spectrometry 10
• Flow Cytometry 65
• Immunohistochemistry 106
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 121
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 57
• Machine Learning 49
• Deep Learning 44
• Cohort Studies 78
• Genome-Wide Association Study 22

• [Comparison of clinical characteristics and MRI functional parameters between choroidal melanoma and choroidal hemangioma].

  Zhonghua Yan Ke Za Zhi, 2026. nov.

• Serum Glial-Related Biomarkers Show Distinct Contributions to Radiologic and Clinical Outcomes in Early Multiple Sclerosis.

  Neurol Neuroimmunol Neuroinflamm, 2026. okt.

• Imaging Manifestations and Clinical Analysis of 12 Cases of Anorectal Malignant Melanoma.

  Ann Ital Chir, 2026. okt.

• Non-invasive Imaging Modalities for Breslow Thickness Estimation in Melanoma: A Scoping Review.

  Skin Res Technol, 2026. okt.

• Influence of metastases composition on the conspicuity of melanoma brain metastases: a comparative study of post-contrast 3D T1WI GRE versus 3D T1WI TSE black blood.

  Radiol Med, 2026. aug.

• Systemic surveillance for uveal melanoma: Approach to optimization.

  PLoS One, 2026. aug.

• Radiomics for risk stratification in brain metastases: potential in melanoma brain metastases.

  Clin Exp Metastasis, 2026. aug.

• Orbital involvement by spindle cell squamous cell carcinoma: a case report of a rare and aggressive tumor with diagnostic challenges.

  BMC Ophthalmol, 2026. júl.

• Clinically presumed primary malignant melanoma of the parotid gland with extensive cervical lymph node metastasis: a case report.

  J Med Case Rep, 2026. júl.

• Artificial intelligence (AI) uses in stereotactic radiosurgery (SRS): diagnosis with brain metastasis (BM) - A systematic review.

  J Clin Neurosci, 2026. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.